ライフサイエンスコーパス: genitourinary

1 , GI (27%), gynecologic (17%), breast (11%), genitourinary (10%), or other (6%) cancer joined this pr

2 These were followed by genitourinary (28%), abdominal (14%) and chest and breas

3 Diseases of digestive (110 922; 16%), genitourinary (82 505; 12%), and musculoskeletal system

4 Patients with Wilms' tumor and aniridia or genitourinary abnormalities should be followed closely t

5 nd fertile, but females exhibited pronounced genitourinary abnormalities that included vaginal and ut

6 including the WAGR (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation) reg

7 a, structural CNS malformations, ataxia, and genitourinary abnormalities.

8 gic anomalies, congenital heart defects, and genitourinary abnormalities.

9 hin the homeodomain produce typical limb and genitourinary abnormalities; in family 4, an expansion o

10 r 8.2 weeks, although an increase in late GI/genitourinary adverse events was observed in patients tr

11 Late grade 2 and 3 GI and genitourinary adverse events were increased (HR, 1.31 to

12 Acute genitourinary and gastrointestinal toxicity as defined b

13 ack and limbs can be affected as well as the genitourinary and gastrointestinal tracts.

14 e detected between arms for grade >/= 3 late genitourinary and GI toxicity.

15 r probability of experiencing 30- and 90-day genitourinary and miscellaneous medical complications (a

16 whole-gland therapy can lead to significant genitourinary and rectal side-effects for men with local

17 nts (70% gastrointestinal, 21% epistaxis, 3% genitourinary, and 6% intracranial).

18 critical roles in the immune, reproductive, genitourinary, and auditory systems.

19 the mucosal epithelia of human respiratory, genitourinary, and digestive tracts.

20 luded cardiac, respiratory, vascular, wound, genitourinary, and miscellaneous surgical and medical co

21 ially in endoscopy, laparoscopy, gynecology, genitourinary, and orthopedics.

22 autonomic cardiovascular, gastrointestinal, genitourinary, and sudomotor symptoms in all subjects.

23 ed histology, primary tumor sites other than genitourinary, and treatment on IRS-I or II.

24 or suppressor gene WT1 results in a range of genitourinary anomalies in humans, including 46,XY gonad

25 n of newborn Noggin-/- male fetuses revealed genitourinary anomalies including cryptorchidism, incomp

26 4%) anomalies; interestingly, this group had genitourinary anomalies more frequently (47%) compared t

27 14.1), result in the Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation (WAGR) s

28 of WAGR syndrome for Wilm's tumor, aniridia, genitourinary anomalies, and mental retardation) is a ra

29 Unlike WAGR (Wilms tumor, aniridia, genitourinary anomalies, and mental retardation) syndrom

30 GR syndrome (the clinical triad of aniridia, genitourinary anomalies, and mental retardation, a subgr

31 led to aniridia, polycystic kidney disease, genitourinary anomalies, and mental retardation, similar

32 e who did not have characteristic congenital genitourinary anomalies, and their risk was <1%.

33 ions in patients with WT are associated with genitourinary anomalies, especially cryptorchidism and/o

34 onosis and the absence of kidneys with other genitourinary anomalies, expression of the Ret(H)(2B) tr

35 ndrome characterized by distal extremity and genitourinary anomalies, is caused by mutations in the H

36 powerful tool for the diagnosis of pediatric genitourinary anomalies.

37 ed to be useful in the evaluation of complex genitourinary anomalies.

38 rt first metacarpals, facial dysmorphism and genitourinary anomalies.

39 eal dysfunction; cardiac, ophthalmologic and genitourinary anomalies; hirsutism; and characteristic f

40 ad significantly diminished weights of their genitourinary apparatuses and dorsolateral and ventral p

41 s been directly implicated in numerous other genitourinary as well as extragenitourinary tract pathol

42 ion of the reproductive tract and results in genitourinary birth defects in humans.

43 site, retroperitoneal, gastrointestinal, or genitourinary bleeding; intracranial hemorrhage; cardiac

44 0.0), colorectal cancer (7.0%, 6.1-8.0), and genitourinary cancer (5.6%, 4.5-6.7).

45 CI], 1.15-2.02; P = 0.004), particularly for genitourinary cancer (adjusted HR, 1.79; 95% CI, 1.03-3.

46 onneoplastic urinary tract disease (n = 30), genitourinary cancer (n = 30), new-onset or recurrent bl

47 Urine from 91 patients without genitourinary cancer and serum from 30 age-matched nonca

48 vant chemotherapies to kill gastrointestinal/genitourinary cancer cells.

49 inicians (physicians and nurses) in lung and genitourinary cancer clinics in the Memorial Sloan-Kette

50 from 91 control subjects without evidence of genitourinary cancer revealed no methylation of the MGMT

51 les from the 91 controls without evidence of genitourinary cancer revealed no methylation of the p16,

52 st cancer, sarcoma, gastrointestinal cancer, genitourinary cancer, gynaecological cancer, thoracic ca

53 nal information is available at www.asco.org/genitourinary-cancer-guidelines and www.asco.org/guideli

54 Genitourinary cancers are the second most common tumors

55 A pathologist with expertise in genitourinary cancers assigned Gleason scores to the pro

56 cular biologic events involved in children's genitourinary cancers continue to advance treatment.

57 f Hodgkin lymphoma, acute myeloid leukaemia, genitourinary cancers other than bladder cancer, non-Hod

58 are chemotherapy agents for gastrointestinal/genitourinary cancers represents a novel modality.

59 carcinoma (CC-RCC) is the most lethal of all genitourinary cancers.

60 ble for cervical, oropharyngeal, and various genitourinary cancers.

61 increasing case detection by 44.3% from 300 genitourinary cases to 433 total cases, ranging from 21.

62 ared between rectal-only chlamydia cases and genitourinary cases using chi(2) or Fisher exact test, M

63 Congenital malformations of anorectal and genitourinary (collectively, anogenital) organs occur at

64 cognitive), somatic (muscular), respiratory, genitourinary complaints; and depressed behavior were mo

65 RRP was associated with an increased risk of genitourinary complications (4.7% vs 2.1%; P = .001) and

66 tional cancer therapies but experienced more genitourinary complications, incontinence, and erectile

67 ons (46.0%), gynecologic conditions (21.6%), genitourinary conditions (16.9%), and hepatopancreaticob

68 ever (n = 281; 13%), and gastrointestinal or genitourinary conditions (n = 268; 12%), among others.

69 Despite the fact that genitourinary defects are among the most common birth de

70 Genitourinary defects resulting from disruption of AR ac

71 nt for the association between anorectal and genitourinary defects.

72 The GenitoUrinary Development Molecular Anatomy Project (GUD

73 llular functions critical for nephrogenesis, genitourinary development, haematopoiesis and sex determ

74 rgan (skin appendage, breast, prostate), and genitourinary development.

75 Presented here is a brief overview of the Genitourinary Developmental Molecular Anatomy Project ef

76 There are three components to the Genitourinary Developmental Molecular Anatomy Project GU

77 s in the levator ani muscle (n = 34) and the genitourinary diaphragm (n = 28).

78 emonstrable correlation with periurethral or genitourinary diaphragm seed implantation or with signal

79 ation or with signal intensity change in the genitourinary diaphragm.

80 lation of target genes related to apoptosis, genitourinary differentiation, and cell cycle progressio

81 ory disease (RR = 1.19, 95% CI: 1.02, 1.39), genitourinary disease (RR = 1.39, 95% CI: 1.07, 1.82), a

82 d specificity in patients with non-malignant genitourinary disease or other disorders.

83 those with other malignant and non-malignant genitourinary disease ranged from 86% to 100%.

84 viduals, and 138 patients with non-malignant genitourinary disease.

85 nd patients with malignant and non-malignant genitourinary disease.

86 1; surgical 2.62, 1.69-4.06, p<0.0001), or a genitourinary disorder (2.19, 1.43-3.36, p=0.0003).

87 enerative disorders also affect respiration, genitourinary function and sleep.

88 A basic assessment of facial, skeletal, genitourinary, gastrointestinal and integumentary abnorm

89 rm, and includes taillessness and severe gut/genitourinary (GGU) malformations.

90 ) significant decrease in prostate (64%) and genitourinary (GU) (72%) weight, (iii) significant inhib

91 Rates of late genitourinary (GU) and GI toxicity were assessed using t

92 grade 2 and two patients (0.6%) had grade 3 genitourinary (GU) baseline symptoms.

93 ons in Hoxa13 cause malformation of limb and genitourinary (GU) regions.

94 f UTI and STI in adult women presenting with genitourinary (GU) symptoms or diagnosed with GU infecti

95 or lower tract (reproductive organs) of the genitourinary (GU) system are fundamentally linked by th

96 CS-sorted components of the developing mouse genitourinary (GU) system.

97 Gastrointestinal (GI) and genitourinary (GU) toxicities were reviewed for each of

98 ity (DLT) was defined as grade 3 or worse GI/genitourinary (GU) toxicity by Common Terminology Criter

99 pithelial cells in the kidney and developing genitourinary (GU) tract.

100 pithelial cells in the kidney and developing genitourinary (GU) tract.

101 s; we used a random effects model to compare genitourinary (GU), GI, and other toxicity between match

102 rectal (gastrointestinal [GI]) and urinary (genitourinary [GU]) symptoms in 35% and 48% of patients,

103 al atresia, retarded growth and development, genitourinary hypoplasia and ear abnormalities.

104 with urolithiasis lends support for routine genitourinary imaging in order to identify and treat tho

105 ears, there has been a dramatic evolution in genitourinary imaging.

106 iomyopathy or other cardiac disease (18.3%), genitourinary infection (11.5%), complications from ecto

107 y infection (OR = 1.00, 95% CI: 0.99, 1.01), genitourinary infection (OR = 1.01, 95% CI: 0.99, 1.02),

108 Genitourinary infections (GUIs) have been associated wit

109 These results suggest that early genitourinary infections may contribute to later develop

110 Gestational genitourinary infections, which have been associated wit

111 s over the past 3 years in the management of genitourinary injuries, surgical wounds, and complicatio

112 For men with significant genitourinary injury, penile transplantation is being co

113 process, and the patients' pain response to genitourinary insults.

114 icities between the 2 groups (late-grade 3-4 genitourinary <3%; gastrointestinal <4%).

115 ul human pathogen associated with a range of genitourinary maladies.

116 S) and WAGR syndrome (Wilms tumor, aniridia, genitourinary malformations, and mental retardation).

117 Patients with Wilms' tumor, aniridia, major genitourinary malformations, and mental retardation, the

118 ial defects, clavicular hypoplasia, anal and genitourinary malformations, and skin eruption.

119 nital phase causes coordinated anorectal and genitourinary malformations, whereas inactivation during

120 fect digital arch structures and can involve genitourinary malformations.

121 Bladder cancer is one of the most common genitourinary malignancies and is a potentially life-thr

122 The major genitourinary malignancies and their management will be

123 mutations predispose to gastrointestinal and genitourinary malignancies in a cancer predisposition sy

124 ndritic cell-based vaccines to patients with genitourinary malignancies showed low toxicity profiles,

125 States in 2005, making it the most lethal of genitourinary malignancies.

126 ancer continues to be one of the most common genitourinary malignancies.

127 e-matched individuals without any history of genitourinary malignancy as controls.

128 14 individuals without clinical evidence of genitourinary malignancy served as controls.

129 d on the basis of the results of a survey of genitourinary medical oncologists.

130 Diagnoses of genital warts (GW) in genitourinary medicine (GUM) clinics have been increasin

131 ess of offering vaccination to MSM who visit genitourinary medicine (GUM) clinics.

132 cutive patients with gonorrhea attending the Genitourinary Medicine clinic in Sheffield, United Kingd

133 llected by a cross-sectional survey of 2,203 genitourinary medicine clinic patients in England in 200

134 recruited 82 participants from an outpatient genitourinary medicine clinic.

135 ing clinical trial was conducted in European genitourinary medicine clinics between December 20, 2001

136 Programme (GRASP) for patients attending 26 genitourinary medicine clinics in England and Wales betw

137 e in consecutive gonococcal isolates from 26 genitourinary medicine clinics in England and Wales.

138 Of 197 eligible patients from genitourinary medicine clinics, 161 accessed results onl

139 were untreated patients with chlamydia from genitourinary medicine clinics, untreated patients with

140 xually transmitted infection, the ability of genitourinary medicine services to provide appropriate a

141 re a part of the normal gastrointestinal and genitourinary microbiota and have rarely been reported t

142 In the genitourinary MR imaging radiologist group of patients,

143 Readers of MR images were classified into genitourinary MR imaging radiologists (n = 4) and genera

144 rve with endorectal MR images interpreted by genitourinary MR imaging radiologists (P =.019 and.31, r

145 skin cancer (n = 278), digestive (n = 105), genitourinary (n = 100), breast (n = 97), and bone (n =

146 at older than 40 years was for digestive and genitourinary neoplasms.

147 rwent inpatient general, vascular, thoracic, genitourinary, neurosurgical, orthopedic, or spine surge

148 tain features that promote adaptation to the genitourinary niche, making them gonococcus-like and dis

149 Patients with genitourinary nonbladder prostate tumors had the most fa

150 neck [not orbit/eyelid or parameningeal] and genitourinary [not bladder or prostate]) improved from 7

151 The therapeutic armamentarium available to genitourinary oncologists continues to grow, but much wo

152 No significant differences in acute genitourinary or gastrointestinal toxicity were observed

153 rences in rectal or bladder dose or in acute genitourinary or gastrointestinal toxicity.

154 rences in rectal or bladder dose or in acute genitourinary or gastrointestinal toxicity.

155 s not recommended for patients who undergo a genitourinary or gastrointestinal tract procedure.

156 nded manner for classification of those with genitourinary or oropharyngeal symptoms.

157 eceiving chemotherapy for lung, gynecologic, genitourinary, or breast cancer at a tertiary cancer cen

158 from patients with breast, lung, colorectal, genitourinary, or gynaecological cancer who had particip

159 e the role of various signaling molecules in genitourinary organogenesis.

160 ), breast (7.6%), gynecologic organs (7.1%), genitourinary organs (4.2%), esophagus (3.6%), skin (mel

161 malies that affect sexual differentiation of genitourinary organs and secondary sex characters.

162 gle-organ vasculitis affecting abdominal and genitourinary organs, breast and aorta have been reporte

163 uired for normal patterning of digestive and genitourinary organs.

164 important role in proper development of the genitourinary organs.

165 ascular p < 0.01; gastrointestinal p < 0.01; genitourinary p < 0.01) and autonomic function tests (p

166 A genitourinary pathologist blinded to MP MR findings outl

167 s, including depression, constipation, pain, genitourinary problems, and sleep disorders, can be impr

168 ith pulmonary, gastrointestinal, cardiac, or genitourinary procedures or with surgery.

169 Because genitourinary procedures were not included during the fi

170 ion of ECE when MR images are interpreted by genitourinary radiologists experienced with MR imaging o

171 Two nuclear medicine and 2 genitourinary radiologists independently and in a masked

172 ction between gastrointestinal radiology and genitourinary radiology, as both organ systems are image

173 nary sphincters, and testicular implants for genitourinary reconstruction for erectile dysfunction, i

174 al functions affected by treatment including genitourinary, rectal, and sexual functions.

175 ltifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of ea

176 In rhabdomyosarcoma, genitourinary site and embryonal histology confer a rela

177 strains, only one of which was from a female genitourinary source, produced cellular fatty acid and b

178 f sepsis in males (36% vs. 29%, p < .01) and genitourinary sources in females (35% vs. 27%, p < .01).

179 To review the progress of the genitourinary SPORE (Specialized Program of Research Exc

180 has become one of the primary focuses of the genitourinary SPORE in bladder cancer.

181 hogens, organisms, dental, gastrointestinal, genitourinary, streptococcus, enterococcus, staphylococc

182 al and abnormal development of anorectal and genitourinary structures.

183 than 40 years was highest for digestive and genitourinary subsequent primary neoplasms (AER, 5.9 [95

184 Prespecified outcomes were three genitourinary symptoms (bowel function tenderness, frequ

185 the previous 2 months (OR, 1.61), and having genitourinary symptoms (OR, 1.46).

186 genitalium is considered a leading cause of genitourinary symptoms in men and women, extreme difficu

187 The genitourinary syndrome of menopause has a negative impac

188 is usually requires a suspicion of this rare genitourinary syndrome.

189 and a median elapsed time of 15 years in the genitourinary system (35%), head and neck area (32%), ga

190 opy human malformations involving the spine, genitourinary system and distal digestive tract.

191 c role of GATA5 in development of the female genitourinary system and suggest that other GATA factors

192 s approach, we found that development of the genitourinary system and the enteric and autonomic nervo

193 with key roles in normal development of the genitourinary system and tumourigenesis.

194 ents the first example of how the developing genitourinary system integrates cues from systemically c

195 n of WT1 and AOC1 proteins in the developing genitourinary system of mice and rats.

196 In contrast, the genitourinary system was unaffected in male GATA5 mutant

197 de is found in highest levels in the gut and genitourinary system where it potently contracts smooth

198 e in neural crest-derived structures and the genitourinary system.

199 ing congenital and acquired disorders of the genitourinary system.

200 essential for the normal development of the genitourinary system.

201 d subsequently in the lung, vasculature, and genitourinary system.

202 of gastrointestinal, vascular, pulmonary and genitourinary systems.

203 ohn Cunningham virus DNA was found in 75% of genitourinary tissue samples from donors (18 of 24) with

204 es of survival, metastasis, and the ratio of genitourinary tissue weight to body weight were not sign

205 cating) JCV infection mostly predominates in genitourinary tissues but distributes in other tissues a

206 Genitourinary tissues can be engineered in-vitro and in-

207 Genitourinary tissues had higher copy numbers than other

208 t, enhances estrogen receptor action in male genitourinary tissues, affects the virilization of the r

209 persist even after bacterial clearance from genitourinary tissues.

210 studies map the fate of cells in developing genitourinary tissues.

211 ality varied by infection sources (19.1% for genitourinary to 43.0% for respiratory; p < 0.001), by n

212 hysician-assessed late gastro intestinal and genitourinary toxicity greater than or equal to grade 2

213 ts in both arms experienced late grade >/= 3 genitourinary toxicity, and 1% of patients in the high-d

214 4, or 5 (acute or late, gastrointestinal, or genitourinary) toxicity was observed.

215 e intervention group), lung (36%; 58 vs 59), genitourinary tract (12%; 20 vs 19), and breast (10%; 16

216 and pathologic development of the gonads and genitourinary tract and addresses the role of ultrasonog

217 ality of choice for the imaging of pediatric genitourinary tract anomalies.

218 icance of Haemophilus spp. isolated from the genitourinary tract are not well known.

219 requently carried in the gastrointestinal or genitourinary tract as a commensal organism, yet it has

220 There was an excess risk of genitourinary tract cancers among recipients who had exp

221 This case describes a rarely reported non-genitourinary tract clinical isolate of S. pseudoporcinu

222 Six1 and Eya1 genes results in a spectrum of genitourinary tract defects including persistent cloaca

223 Thus, both systemic and local genitourinary tract factors influence the risk of semen

224 ssential roles of the PCM progenitors during genitourinary tract formation.

225 c and functional assessment of the pediatric genitourinary tract in a single study without the use of

226 Because the male genitourinary tract is distinct immunologically from blo

227 re we analyzed children born with congenital genitourinary tract masculinization disorders by array-c

228 opriate management and reconstruction of the genitourinary tract may allow for a planned and preempti

229 he relationships between the male and female genitourinary tract microbiomes, and the development of

230 The pathogenesis of an infection of the male genitourinary tract of mice with a human serovar of Chla

231 eudoporcinus was primarily isolated from the genitourinary tract of women but was also associated wit

232 , a recently described organism found in the genitourinary tract of women, was isolated from a thumb

233 Mycoplasma hominis is a commensal genitourinary tract organism that can cause infections o

234 t reduction (46%, P < 0.01) in the weight of genitourinary tract organs in the GSE-fed mice.

235 ment of patients with a variety of suspected genitourinary tract problems, but the procedures are und

236 s article concludes with a listing of BV and genitourinary tract research priorities that were discus

237 enzae type b genogroup strains isolated from genitourinary tract specimens from an adult male veteran

238 lates of the FCG4b group, mainly from female genitourinary tract specimens, as well as the type strai

239 tly isolated species and was associated with genitourinary tract specimens, often with other organism

240 chomatis MoPn results in an infection of the genitourinary tract that closely parallels that describe

241 The urologist involved in the management of genitourinary tract trauma needs to recognize the patter

242 At 30 weeks of age, the average genitourinary tract weights of TRAMP mice were approxima

243 scardovii isolate was from a patient with a genitourinary tract wound infection, two B. longum isola

244 ents adaptive in extraintestinal niches (the genitourinary tract) but detrimental in the main habitat

245 al sphincter, separating the rectum from the genitourinary tract, and reconstructing the anus.

246 tein is normally expressed in the developing genitourinary tract, heart, spleen and adrenal glands an

247 lformations of the appendicular skeleton and genitourinary tract, including digit loss, syndactyly, a

248 s vaginalis, a parasite adapted to the human genitourinary tract, infects globally approximately 250

249 hominis are associated with infection of the genitourinary tract, reproductive failure, and neonatal

250 for many common congenital anomalies of the genitourinary tract.

251 ited infection mainly localized to the lower genitourinary tract.

252 is impacted by successful management of the genitourinary tract.

253 n in women, colonizes the gut as well as the genitourinary tract.

254 nostic tool for the imaging of the pediatric genitourinary tract.

255 ganism that can cause infections outside the genitourinary tract.

256 elp detect causes for flank pain outside the genitourinary tract.

257 d to be associated with complications to the genitourinary tract.

258 ted condition affecting the distal limbs and genitourinary tract.

259 ating several abnormalities of the pediatric genitourinary tract.

260 a of the oro-intestinal, nasorespiratory, or genitourinary tract.

261 peptide secreted by epithelial cells in the genitourinary tract.

262 mensal organisms of the gastrointestinal and genitourinary tracts and are commonly used as "probiotic

263 ls that line the digestive, respiratory, and genitourinary tracts form a barrier that many viruses mu

264 mensals, colonizing the gastrointestinal and genitourinary tracts in addition to the oral mucosa.

265 body, particularly the gastrointestinal and genitourinary tracts of healthy individuals.

266 us, GBS) is a commensal of the digestive and genitourinary tracts of humans that emerged as the leadi

267 enitalium clinical strains isolated from the genitourinary tracts of women attending a sexually trans

268 lls of the gastrointestinal, respiratory and genitourinary tracts, developing cartilage, pituitary gl

269 were evaluated by wholemount dissections of genitourinary tracts, histology, immunohistochemistry, a

270 is of the vasculature, gastrointestinal, and genitourinary tracts.

271 arteries as well as the gastrointestinal and genitourinary tracts.

272 omes data have impacted on the management of genitourinary trauma and will be likely to influence the

273 review the 2010/2011 literature on pediatric genitourinary tumors and highlight the most significant

274 review the 2009/2010 literature on pediatric genitourinary tumors and highlight the most significant

275 review the 2008-2009 literature on pediatric genitourinary tumors and highlight the most significant

276 Unlike the more common skin malignancies, genitourinary tumors have a significant impact on both g

277 ng made in understanding the pathogenesis of genitourinary tumors in children, and the prognosis for

278 o be made in the evaluation and treatment of genitourinary tumors in children.

279 in the clinical evaluation and treatment of genitourinary tumors in children.

280 are made in the evaluation and management of genitourinary tumors in children.

281 l, the prognosis for patients with pediatric genitourinary tumors is favorable.

282 l, the prognosis for patients with pediatric genitourinary tumors is favorable.

283 l, the prognosis for patients with pediatric genitourinary tumors is favorable.

284 trast, NK cells from patients diagnosed with genitourinary tumors possessed a standard immature signa

285 s past year's literature regarding pediatric genitourinary tumors with emphasis on Wilms tumor, rhabd

286 tumors, such as neuroendocrine carcinoma and genitourinary tumors, are also treated effectively with

287 orary treatments for pediatric patients with genitourinary tumors.

288 orary treatments for pediatric patients with genitourinary tumors.

289 orary treatments for pediatric patients with genitourinary tumors.

290 pments in molecular diagnostics in pediatric genitourinary tumors.

291 review the 2007/2008 literature on pediatric genitourinary tumors.

292 e recent (2006/2007) literature on pediatric genitourinary tumors.

293 ew the 2005 and 2006 literature on pediatric genitourinary tumors.

294 s drive risk-stratified therapy in pediatric genitourinary tumors.

295 We review the 2002 literature on pediatric genitourinary tumors.

296 Bladder cancer is the second most common genitourinary tumour and is a significant cause of morbi

297 es in prostatic volume, urethral volume, and genitourinary vascularization over time in response to e

298 t decrease in prostate (56%; P < 0.0003) and genitourinary weight (48%; P < 0.008).

299 ight (59%) and volume (66%) of prostate, (b) genitourinary weight (63%), and (c) ODC enzyme activity

300 Three PHC donor tumor types (skin, brain, genitourinary) were associated with 549 of the transplan